abstract |
The present invention provides methods of screening subjects for the presence of IL-23R+/PD-1 + gamma-delta T-cells as a marker of autoreactive immune disorders, use of such identification in directing treatment, and related methods of treatment. The invention also provides use of such IL-23R+/PD-1 + gamma-delta T-cells in screening for agents useful in treating autoreactive immune disorders. |